Prana Biotechnology mentioned cautiously at Summer Street Summer Street said it believes Prana Biotechnology 's PBT2 is a "long shot" as a treatment for Alzheimer’s and Huntington’s diseases. The firm is skeptical about PBT2's proposed mechanism. Shares of Prana are trading down 57c to $9.35 in pre-market trading.
News For PRAN From The Last 14 Days
Check below for free stories on PRAN the last two weeks.
Prana granted orphan status for treatment of Huntington disease The FDA posted on its website that Prana Biotechnology has been granted orphan status for its treatment of Huntington's disease. Reference Link